Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.
Rani SoenenZhigang WangLynda GrineErwin DreesenLisa SchotsEls BrouwersPaul J DeclerckDebby ThomasJo Lydie Wilfried LambertPublished in: Clinical and experimental dermatology (2022)
Monitoring and targeting a secukinumab trough concentration of 39.1 mg/L may be a viable treatment option in suboptimal responders. In patients with higher BMI, weight-based dosing may be needed in order to prevent underdosing.